Ether-a-go-go-related gene potassium channels: What's all the buzz about?

Schizophrenia Bulletin

Volumn 33, Issue 6, 2007, Pages 1263-1269

  Shepard, Paul D ^a   Canavier, Carmen C ^b   Levitan, Edwin S ^c  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Bursting; Dopamine; Review; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CISAPRIDE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; POSTSYNAPTIC RECEPTOR; POTASSIUM CHANNEL HERG; QUETIAPINE; RISPERIDONE; SERTINDOLE; TERFENADINE; THIORIDAZINE; ZIPRASIDONE;

CENTRAL NERVOUS SYSTEM; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG FATALITY; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTRIC POTENTIAL; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MEMBRANE TRANSPORT; MESENCEPHALON; NERVE EXCITABILITY; NERVE POTENTIAL; NONHUMAN; POTASSIUM CURRENT; PRESYNAPTIC NERVE; PRIORITY JOURNAL; QT PROLONGATION; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

ANTIPSYCHOTIC AGENTS; BRAIN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 35648982545     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm106     Document Type: Review

References (64)

1. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188:1217-1219.
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481-483.
3. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106S-115S.
4. Calderone V, Testai L, Martinotti E, Del Tacca M, Breschi MC. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics. J Pharm Pharmacol. 2005;57:151-161.
5. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A. 1994;91:3438-3442.
6. Kaplan WD, Trout WE 3rd. The behavior of four neurological mutants of Drosophila. Genetics. 1969;61:399-409.
7. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463-469.
8. Canavier CC, Oprisan S, Callaway J, Ji H, Shepard PD. Computational model predicts a role for ERG current in repolarizing plateau potentials in dopamine neurons: implications for modulation of neuronal activity. J Neurophysiol. 2007;doi: 10.1152/jn.00422.2007.
9. Sacco T, Bruno A, Wanke E, Tempia F. Functional roles of an ERG current isolated in cerebellar Purkinje neurons. J Neurophysiol. 2003;90:1817-1828.
10. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.
11. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269:92-95.
12. Shibasaki T. Conductance and kinetics of delayed rectifier potassium channels in nodal cells of the rabbit heart. J Physiol. 1987;387:227-250.
13. Lees-Miller JP, Kondo C, Wang L, Duff HJ. Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts. Circ Res. 1997;81:719-726.
14. Jones EM, Roti Roti EC, Wang J, Delfosse SA, Robertson GA. Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem. 2004;279:44690-44694.
15. London B, Trudeau MC, Newton KP, et al. Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. Circ Res. 1997;81:870-878.
16. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
17. Delisle BP, Anson BD, Rajamani S, January CT. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res. 2004;94:1418-1428.
18. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther. 2002;301:427-434.
19. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002;450:37-41.
20. Thomas D, Wu K, Kathofer S, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol. 2003;139:567-574.
21. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997;120:968-974.
22. Kang J, Wang L, Cai F, Rampe D. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol. 2000;392:137-140.
23. Lee SY, Kim YJ, Kim KT, Choe H, Jo SH. Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol. 2006;148:499-509.
24. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 1998;286:788-793.
25. Malmberg A, Jackson DM, Eriksson A, Mohell N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol. 1993;43:749-754.
26. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. Journal of Psychiatry and Neuroscience. 2000;25:161-166.
27. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275:101-113.
28. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci. 1995;309:315-316.
29. Mack R, Driscoll R, Silber C. The long term cardiovascularsafety of sertindole. Eur Neuropsychopharmacol. 2002;7:S207.
30. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 2005;28:35-51.
31. Hoehns JD, Stanford RH, Geraets DR, Skelly KS, Lee HC, Gaul BL. Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy. 2001;21:871-883.
32. Crumb WJ Jr, Ekins S, Sarazan RD, et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharmacol Res. 2006;23:1133-1143.
33. Titier K, Canal M, Deridet E, et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol. 2004;199:52-60.
34. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTcinterval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048-1052.
35. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 2000;25:154-160.
36. Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 1996;93:311-313.
37. Wymore RS, Gintant GA, Wymore RT, Dixon JE, McKinnon D, Cohen IS. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. Circ Res. 1997;80:261-268.
38. Shi W, Wymore RS, Wang HS, et al. Identification of two nervous system-specific members of the erg potassium channel gene family. J Neurosci. 1997;17:9423-9432.
39. Papa M, Boscia F, Canitano A, et al. Expression pattern of the ether-a-gogo-related (ERG) K+ channel-encoding genes ERG1, ERG2, and ERG3 in the adult rat central nervous system. J Comp Neurol. 2003;466:119-135.
40. Saganich MJ, Machado E, Rudy B. Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci. 2001;21:4609-4624.
41. Guasti L, Cilia E, Crociani O, et al. Expression pattern of the ether-a-go-go-related (ERG) family proteins in the adult mouse central nervous system: evidence for coassembly of different subunits. J Comp Neurol. 2005;491:157-174.
42. Kang J, Chen XL, Rampe D. The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel. Biochem Biophys Res Commun. 2001;286:499-504.
43. Wu SN, Jan CR, Li HF, Chiang HT. Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells. Neuropsychopharmacology. 2000;23:676-689.
44. Bauer CK, Schafer R, Schiemann D, Reid G, Hanganu I, Schwarz JR. A functional role of the erg-like inwardrectifying K+ current in prolactin secretion from rat lactotrophs. Mol Cell Endocrinol. 1999;148:37-45.
45. Lecchi M, Redaelli E, Rosati B, et al. Isolation of a longlasting eag-related gene-type K+ current in MMQ lactotrophs and its accommodating role during slow firing and prolactin release. J Neurosci. 2002;22:3414-3425.
46. Nedergaard S. A Ca2+-independent slow afterhyperpolarization in substantia nigra compacta neurons. Neuroscience. 2004;125:841-852.
47. + conductance. Exp Brain Res. 1991;86:141-150.
48. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci. 1984;4:2877-2890.
49. Heien ML, Wightman RM. Phasic dopamine signaling during behavior, reward, and disease states. CNS Neurol Disord Drug Targets. 2006;5:99-108.
50. Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neuron by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther. 1986;238:1092-1100.
51. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-263.
52. Overton PG, Clark D. Burst firing in midbrain dopaminergic neurons. Brain Res Rev. 1997;25:312-334.
53. Ji H, Shepard PD. SK Ca2+-activated K+ channel ligands alter the firing pattern of dopamine-containing neurons in vivo. Neuroscience. 2006;140:623-633.
54. Shepard PD, Bunney BS. Effects of apamin on the discharge properties of putative dopamine-containing neurons in vitro. Brain Res. 1988;463:380-384.
55. Johnson SW, Wu YN. Multiple mechanisms underlie burst firing in rat midbrain dopamine neurons in vitro. Brain Res. 2004;1019:293-296.
56. Kass JI, Mintz IM. Silent plateau potentials, rhythmic bursts, and pacemaker firing: three patterns of activity that coexist in quadristable subthalamic neurons. Proc Natl Acad Sci U S A. 2006;103:183-188.
57. Bains JS, Ferguson AV. Hyperpolarizing after-potentials regulate generation of long-duration plateau depolarizations in rat paraventricular nucleus neurons. Eur J Neurosci. 1998;10:1412-1421.
58. Fernandez FR, Engbers JD, Turner RW. Firing dynamics of cerebellar Purkinje cells. J Neurophysiol. 2007;98:278-294.
59. Schwindt P, Crill W. Mechanisms underlying burst and regular spiking evoked by dendritic depolarization in layer 5 cortical pyramidal neurons. J Neurophysiol. 1999;81:1341-1354.
60. Kawasaki H, Palmieri C, Avoli M. Muscarinic receptor activation induces depolarizing plateau potentials in bursting neurons of the rat subiculum. J Neurophysiol. 1999;82:2590-2601.
61. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 1983;221:1054-1057.
62. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997;20:31-37.
63. Wanke E, Restano-Cassulini R. Toxins interacting with ether-a-go-go-related gene voltage-dependent potassium channels. Toxicon. 2007;49:239-248.
64. Strobaek D, Hougaard C, Johansen TH, et al. Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons. Mol Pharmacol. 2006;70:1771-1782.